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Hepatitis C (HCV) is a highly prevalent blood-borne virus with infection of 2-3% of world population and high rate 
of chronicity (>70%) leading to chronic hepatitis, which often progress to cirrhosis and hepatocellular carcinoma.  
HCV- specific immune responses consisting of CD4 and CD8 T cells and virus neutralizing antibodies have 
been shown to eliminate HCV infections in humans and chimpanzees. Therefore, vaccines that can induce 
potent and durable anti-HCV T and B cell responses may have the potential to clear chronic HCV infections. A 
number of HCV vaccines have been tested clinically with limited success. One of the major limitations in 
developing effective HCV therapies is the lack of effective and reliable animal models due to the narrow host 
range of the HCV virus. The study described herein reports the generation of a murine hepatoma cell line 
expressing HCV non-structural proteins and its use in a metastatic tumor setting to test anti-tumor efficacy of 
bacterial and viral vector vaccines expressing the HCV non-structural genes. HCV-recombinant hepatoma cells 
formed large solid-mass tumors when implanted into syngeneic mice, allowing the testing of HCV vaccines for 
immunogenicity and anti-tumor efficacy.  Using this model, we tested the therapeutic potential of recombinant 
anti-HCV-specific vaccines based on two fundamentally different attenuated pathogen vaccine systems - 
attenuated Salmonella and recombinant adenoviral vector based vaccine. Attenuated Salmonella secreting HCV 
antigens limited growth of the HCV-recombinant tumors when used in a therapeutic vaccination setting. The 
inhibition of tumor growth by Salmonella vector-based vaccines was significantly reduced in mice co-injected 
with an anti-CD8 antibody, suggesting a role by CD8+ cells in the vaccine efficacy. The model was also used to 
compare replication deficient and replication-competent but non-infectious adenoviral vectors expressing non-
structural HCV antigens. Results showed overall greater survival and reduced weight loss with the replication-
competent vector compared to the non-replicating vector. Our results demonstrate the novel recombinant 
murine hepatoma model expressing HCV non-structural antigens as a useful model for evaluating therapeutic 
vaccines against HCV. Vaccines that are capable of inducing potent anti-HCV immune responses that are 
capable of controlling aggressive and metastatic tumor growth in this model would likely have the potential to 
control chronic viral infections such as HCV. This novel approach is particularly interesting for the development 
of therapeutic vaccines. 
 
  
